Aldeyra Therapeutics
ALDX
126 hedge funds and large institutions have $63.3M invested in Aldeyra Therapeutics in 2026 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 37 reducing their positions, and 29 closing their positions.
64% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $823K
35% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.77% less ownership
Funds ownership: 64.77% → 62% (-2.8%)
7% less funds holding
Funds holding: 135 → 126 (-9)
21% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 29
69% less capital invested
Capital invested by funds: $202M → $63.3M (-$138M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$7.02M |
| 2 |
Millennium Management
New York
|
+$4.17M |
| 3 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$3.2M |
| 4 |
Jane Street
New York
|
+$2.91M |
| 5 |
Renaissance Technologies
New York
|
+$2.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$21.7M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$5.08M |
| 3 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$2.19M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.17M |
| 5 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
-$1.16M |
ALDX Hedge Fund Activity: Q1 2026 in Review
126 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2026, worth a combined $63.3M — down 69% from $202M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ALDX and 23 opened new positions — a net loss of 6 holders — while 37 trimmed existing stakes and 50 added.
The largest buyer was AQR Capital Management, adding an estimated $7.02M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $21.7M sold.
- 126 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2026, down from 135 in Q4 2025.
- Funds reported $63.3M of Aldeyra Therapeutics stock for Q1 2026, down 69% quarter-over-quarter.
- 23 funds opened new Aldeyra Therapeutics positions in Q1 2026 and 29 closed out, a net change of -6 holders.
- The largest Aldeyra Therapeutics buyer in Q1 2026 was AQR Capital Management, an estimated $7.02M added.
- The largest Aldeyra Therapeutics seller in Q1 2026 was Perceptive Advisors, an estimated $21.7M sold.
Based on aggregated 13F filings for Q1 2026.